Antithrombin III

Antithrombin replacement during administration of heparin in therapeutic dosage increases the risk of bleeding. The effect of antithrombin is greatly enhanced by heparin. The half-life of antithrombin may be considerably decreased with concomitant heparin treatment due to accelerated antithrombin turnover. Therefore, the concurrent administration of heparin and antithrombin to a patient with an increased risk of bleeding must be monitored clinically and biologically and considered very carefully. If it is decided to use heparin, only standard heparin in low doses should be given.

Experience as to the safety of human antithrombin products for use in human pregnancy is limited. Atenativ should be administered to pregnant and lactating antithrombin deficient women only if clearly indicated, taking into consideration that pregnancy confers an increased risk of thromboembolic events in these patients.

Experience as to the safety of human antithrombin products for use in human pregnancy is limited.

Antithrombin should be administered to pregnant antithrombin deficient women only if clearly indicated, taking into consideration that pregnancy confers an increased risk of thromboembolic events in these patients.

Experience as to the safety of human antithrombin products for use during breast feeding is limited.

Antithrombin should be administered to lactating antithrombin deficient women only if clearly indicated, taking into consideration that pregnancy confers an increased risk of thromboembolic events in these patients.

Antithrombin has no or negligible influence on the ability to drive and use machines.